Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard N Channick

Showing results (71-80 of 106) with videos related to

Pageof 11
Sort By:
Advances in Therapy|July 12, 2022
Long-Term Safety, Tolerability and Survival in Patients with Pulmonary Arterial Hypertension Treated with Macitentan: Results from the SERAPHIN Open-Label ExtensionRogério Souza, Marion Delcroix, Nazzareno Galié, et al.
American Journal of Physiology. Cell Physiology|February 3, 2007
Function of Kv1.5 channels and genetic variations of KCNA5 in patients with idiopathic pulmonary arterial hypertensionCarmelle V Remillard, Donna D Tigno, Oleksandr Platoshyn, et al.
Chest|February 5, 2021
Relationship Between Time From Diagnosis and Morbidity/Mortality in Pulmonary Arterial Hypertension: Results From the Phase III GRIPHON StudySean Gaine, Olivier Sitbon, Richard N Channick, et al.
Cardiovascular Therapeutics|September 14, 2012
Rapid transition from inhaled iloprost to inhaled treprostinil in patients with pulmonary arterial hypertensionRobert C Bourge, Victor F Tapson, Zeenat Safdar, et al.
Journal of the American College of Cardiology|June 27, 2009
Updated clinical classification of pulmonary hypertensionGérald Simonneau, Ivan M Robbins, Maurice Beghetti, et al.
Circulation|November 3, 2025
Randomized Controlled Trial of Mechanical Thrombectomy With Anticoagulation Versus Anticoagulation Alone for Acute Intermediate-High Risk Pulmonary Embolism: Primary Outcomes From the STORM-PE TrialRobert A Lookstein, Stavros V Konstantinides, Ido Weinberg, et al.
European Heart Journal|March 23, 2017
SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertensionNazzareno Galiè, Pavel Jansa, Tomás Pulido, et al.
Pulmonary Circulation|September 10, 2013
Circulating angiogenic modulatory factors predict survival and functional class in pulmonary arterial hypertensionRajeev Malhotra, Samuel Paskin-Flerlage, Roham T Zamanian, et al.
The European Respiratory Journal|October 24, 2015
Incident and prevalent cohorts with pulmonary arterial hypertension: insight from SERAPHINGérald Simonneau, Richard N Channick, Marion Delcroix, et al.
Chest|September 28, 2016
Macitentan Improves Health-Related Quality of Life for Patients With Pulmonary Arterial Hypertension: Results From the Randomized Controlled SERAPHIN TrialSanjay Mehta, Bhagavatula Kutumba Srinivasa Sastry, Rogério Souza, et al.
Pageof 11

Showing results (71-80 of 106) with videos related to

Sort By:
Pageof 11
Advances in Therapy|July 12, 2022
Long-Term Safety, Tolerability and Survival in Patients with Pulmonary Arterial Hypertension Treated with Macitentan: Results from the SERAPHIN Open-Label ExtensionRogério Souza, Marion Delcroix, Nazzareno Galié, et al.
American Journal of Physiology. Cell Physiology|February 3, 2007
Function of Kv1.5 channels and genetic variations of KCNA5 in patients with idiopathic pulmonary arterial hypertensionCarmelle V Remillard, Donna D Tigno, Oleksandr Platoshyn, et al.
Chest|February 5, 2021
Relationship Between Time From Diagnosis and Morbidity/Mortality in Pulmonary Arterial Hypertension: Results From the Phase III GRIPHON StudySean Gaine, Olivier Sitbon, Richard N Channick, et al.
Cardiovascular Therapeutics|September 14, 2012
Rapid transition from inhaled iloprost to inhaled treprostinil in patients with pulmonary arterial hypertensionRobert C Bourge, Victor F Tapson, Zeenat Safdar, et al.
Journal of the American College of Cardiology|June 27, 2009
Updated clinical classification of pulmonary hypertensionGérald Simonneau, Ivan M Robbins, Maurice Beghetti, et al.
Circulation|November 3, 2025
Randomized Controlled Trial of Mechanical Thrombectomy With Anticoagulation Versus Anticoagulation Alone for Acute Intermediate-High Risk Pulmonary Embolism: Primary Outcomes From the STORM-PE TrialRobert A Lookstein, Stavros V Konstantinides, Ido Weinberg, et al.
European Heart Journal|March 23, 2017
SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertensionNazzareno Galiè, Pavel Jansa, Tomás Pulido, et al.
Pulmonary Circulation|September 10, 2013
Circulating angiogenic modulatory factors predict survival and functional class in pulmonary arterial hypertensionRajeev Malhotra, Samuel Paskin-Flerlage, Roham T Zamanian, et al.
The European Respiratory Journal|October 24, 2015
Incident and prevalent cohorts with pulmonary arterial hypertension: insight from SERAPHINGérald Simonneau, Richard N Channick, Marion Delcroix, et al.
Chest|September 28, 2016
Macitentan Improves Health-Related Quality of Life for Patients With Pulmonary Arterial Hypertension: Results From the Randomized Controlled SERAPHIN TrialSanjay Mehta, Bhagavatula Kutumba Srinivasa Sastry, Rogério Souza, et al.
Pageof 11